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Abstract
We have shown that tissue-type plasminogen activator (tPA) and
plasma kallikrein share a common pathway for liver clearance and that
the hepatic clearance rate of plasma kallikrein increases during the
acute-phase (AP) response. We now report the clearance of tPA from
the circulation and by the isolated, exsanguinated and in situ perfused
rat liver during the AP response (48-h ex-turpentine treatment). For
the sake of comparison, the hepatic clearance of a tissue kallikrein and
thrombin was also studied. We verified that, in vivo, the clearance of
125I-tPA from the circulation of turpentine-treated rats (2.2 – 0.2 ml/
min, N = 7) decreases significantly (P = 0.016) when compared to
normal rats (3.2 – 0.3 ml/min, N = 6). The AP response does not
modify the tissue distribution of administered 125I-tPA and the liver
accounts for most of the 125I-tPA (>80%) cleared from the circulation.
The clearance rate of tPA by the isolated and perfused liver of
turpentine-treated rats (15.5 – 1.3 µg/min, N = 4) was slower (P =
0.003) than the clearance rate by the liver of normal rats (22.5 – 0.7 µg/
min, N = 10). After the inflammatory stimulus and additional Kupffer
cell ablation (GdCl3 treatment), tPA was cleared by the perfused liver
at 16.2 – 2.4 µg/min (N = 5), suggesting that Kupffer cells have a
minor influence on the hepatic tPA clearance during the AP response.
In contrast, hepatic clearance rates of thrombin and pancreatic kal-
likrein were not altered during the AP response. These results contri-
bute to explaining why the thrombolytic efficacy of tPA does not
correlate with the dose administered.
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Introduction
Activation of the blood coagulation sys-
tem under physiological or pathological con-
ditions is responsible for the formation of
intravascular fibrin clots (1,2). Clot dissolu-
tion is a process essential for the mainte-
nance of blood fluidity and is achieved by the
proteolysis of fibrin by plasmin. Tissue-type
plasminogen activator (tPA) is the physi-
ological initiator of fibrinolysis, converting
plasminogen into plasmin via specific pro-
teolysis. Because of its fibrin-selective ac-
tion, tPA has been successfully used for
thrombolytic therapy. Since the elimination
of tPA from the circulation is relatively rapid
120
Braz J Med Biol Res 33(1) 2000
M.R. Nagaoka et al.
(4-6 min in humans), high doses of tPA are
required to obtain thrombolysis (3). The liver
is the major site for tPA clearance from the
circulation and the two most important he-
patic receptors for tPA clearance are the
low-density-lipoprotein-receptor-related pro-
tein (LRP) on parenchymal cells and the
mannose receptor on liver endothelial and
Kupffer cells. Other receptors marginally
contribute to tPA clearance (4).
The liver response to injury occupies a
central position in the acute-phase (AP) re-
sponse. The hepatic modulation of the kal-
likrein-kinin system is altered during the AP
response to inflammation, with an increase
in hepatic synthesis of total kininogen (5), T-
kininogen (6) and prokallikrein (7). The kal-
likrein-kinin system is important in the patho-
genesis of the inflammatory reaction (8) and
is linked to the fibrinolytic system since
bradykinin is a potent stimulus of tPA secre-
tion (9).
It has been shown that plasma levels of
tPA and the complex formed by tPA with
plasminogen-activator inhibitor type 1 (PAI-
1) are increased in patients with various liver
diseases (10), perhaps because of impaired
tPA clearance. During the AP response the
clearance rate of plasma-kallikrein by the
perfused rat liver increases (11); in contrast,
the liver uptake of an asialoglycoprotein de-
creases during the AP response (12), sug-
gesting that the mechanism of endocytosis
mediated by different lectins is distinctly
modified during the AP response. We have
shown that tPA and plasma kallikrein share a
common pathway for liver clearance (13).
We now report the clearance of tPA from the
circulation (in vivo) and by the isolated,
exsanguinated and perfused rat liver during
the AP response. For the sake of compari-
son, we also studied the hepatic clearance
of porcine pancreatic kallikrein (PoPK),
which is cleared through the mannose recep-
tor (14), and thrombin (TH), which binds
to liver cells but is minimally internalized
(15).
Material and Methods
Chemicals
Recombinant human tPA (Actilysefi) pro-
vided by Boehringer Ingelheim (Mannheim,
Germany) was used for liver perfusion ex-
periments; melanoma tPA from Calbiochem
(San Diego, CA, USA) was iodinated and
used for in vivo experiments. Na125I was
obtained from Amersham (Buckingham,
UK). Rat plasma thrombin and porcine pan-
creatic kallikrein were purchased from Sigma
Chemical Co. (St. Louis, MO, USA). Acetyl-
phenylalanine-arginine-pnitroanilide (Ac-
Phe-Arg-pNA) was synthesized by L. Juliano
(Department of Biophysics, UNIFESP, SP,
Brazil). The amidolytic substrates S2238 (H-
D-Phe-Pip-Arg-pNA) for thrombin and
S2288 (H-D-Ile-Pro-Arg-pNA) for tPA were
purchased from Chromogenix (Mölndal,
Sweden).
Rats
Adult male Wistar rats weighing 150-
265 g were used according to the Interna-
tional Guiding Principles for Biomedical
Research Involving Animals (16).
Inflammatory stimulus
To study the influence of the AP re-
sponse on the hepatic clearance of tPA, TH
and PoPK, rats received 0.5 ml turpentine oil
subcutaneously at each of two sites on either
side of the abdomen 48 h before the experi-
ment. The AP response was confirmed by
the detection of serum a2macroglobulin
(a2M) by radial immunodiffusion (5). The
specific antibody was donated by A.H. Gor-
don, National Institute for Medical Research,
London.
To determine the participation of Kupffer
cells in the clearance of tPA by the liver of
turpentine-treated rats, GdCl3 dissolved in
0.15 M NaCl was injected through the tail
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vein at the dose of 10 mg/kg (17) 12 h after
turpentine oil injection. The experiments
were conducted 36 h after GdCl3 injection.
tPA labeling
tPA (100 µg) in 0.05 M sodium phos-
phate, pH 7.4, was iodinated with 125I (1
mCi) using the chloramine T method (18).
Unincorporated iodine was removed by gel
filtration on a PD-10 column and eluted with
50 mM sodium phosphate, pH 7.4. The
amidolytic activity upon S2288 and radioac-
tivity of the aliquots were determined. A
preparation of 125I-tPA with a specific radio-
activity of 2.5 x 106 cpm/µg protein was
used.
Amidolytic activity
The amidolytic activity of tPA, TH or
PoPK was assayed by incubating perfusate
aliquots (0.1 ml) at 37oC in a final volume
(0.2 ml) of 50 mM Tris-HCl, 12 mM NaCl,
pH 8.0, for tPA, 15 mM Tris-HCl, 20 mM
EDTA, pH 7.4, for TH, and 50 mM Tris-
HCl, 1 mM EDTA, pH 9.0, for PoPK, at a
final concentration of 0.5 mM S2288, 0.5
mM S2238 and 0.6 mM Ac-Phe-Arg-pNA,
respectively (19). The reaction was stopped
with 0.8 ml of 15% acetic acid and the
absorbance of p-nitroaniline was measured
at 405 nm. Duplicate assays were conducted
and values varied less than 5%.
Clearance of tPA from the circulation
Clearance of 125I-tPA from the circula-
tion was determined in rats anesthetized with
urethane (1.3 mg/g). Tracheotomy was per-
formed and catheters were positioned into
the left jugular vein and right carotid artery.
125I-tPA (2 x 106 cpm, 0.7 µg) plus 500 µg of
unlabeled tPA was injected intravenously in
bolus and flushed with 0.5 ml of 0.15 M
NaCl solution. Blood samples were collected
at 2, 5, 10, 20, 30, 40, 50 and 60 min after
administration of 125I-tPA from the carotid
artery catheter into polyethylene tubes con-
taining 0.4% sodium citrate. The aliquots
were centrifuged at 5000 g for 10 min, and
the plasma samples (150 µl) separated and
precipitated with 10% trichloroacetic acid.
The radioactivity of the acid precipitable
protein was determined with a g-radiation
counter.
To analyze the tissue distribution of 125I-
tPA, 60 min after its administration the ab-
domen and thorax were opened and liver,
heart, lung, kidney and spleen were removed
and weighed and their radioactivity was meas-
ured.
Liver perfusion in situ
The livers were perfused at 37oC as de-
scribed (20). Rats were anesthetized with
urethane (1.3 mg/g) and kept alive by artifi-
cial respiration. The livers were perfused
through the portal vein (inflow cannula) and
thoracic inferior vena cava (outflow can-
nula) in an open circuit with 200 ml of
Krebs-Henseleit bicarbonate solution, pH 7.4.
The circuit was then closed and the livers
were perfused with 30 ml of recirculating
Krebs solution containing 1 mg/ml bovine
serum albumin (BSA) for 10 min, at a con-
stant flow of 28 ml/min. The recirculating
Krebssolution was exchanged with the same
volume of Krebs/BSA and a new equilibra-
tion period of 10 min was allowed to elapse.
The peristaltic pump was then turned off and
500 µg tPA, 50 µg TH or 160 µg PoPK was
added. After 1 min of mixing and collection
of aliquot 0, the peristaltic pump was turned
on and the perfusion reinitiated. Aliquots (1
ml) of the perfusate were collected at 0, 5, 10
and 20 min for tPA, 0, 1, 3, 5 and 10 min for
TH, and 0, 10, 20 and 30 min for PoPK
experiments.
The percentage (aliquot 0 taken as
100%) of the residual amidolytic activity in
the perfusate aliquots was used to calculate
the half-life of disappearance (t‰) and the
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clearance rate of the proteases (with the aid
of the GraphPAD Prism software, version
1.03). The results are reported as mean –
SEM and significant differences were deter-
mined using the Primer computer software
version 3.02 (McGraw-Hill, Inc., New York,
NY, USA).
To exclude possible interference with the
amidolytic activities of tPA, TH or PoPK by
substances liberated from the perfused liver
into the perfusion medium, we incubated the
perfusion medium obtained after 30 min of
perfusion (without any protease added) with
the enzymes.
In anhepatic experiments, i.e., a system
without liver but with the other perfusion
procedures maintained, tPA, TH or PoPK
were recirculated for 15-30 min and the
amidolytic activities assayed.
Results
Control experiments
The in vitro assays showed that the liver
perfusate neither inhibited nor increased the
activity of the enzymes studied (tPA, TH or
PoPK). In anhepatic experiments we ob-
served that tPA, TH or PoPK were not inac-
tivated after 15-30 min of recirculation.
The AP response was confirmed by the
detection of a2M in the serum of turpentine-
and/or GdCl3-treated rats; a2M was not de-
tected in the serum of normal rats.
To determine that Kupffer cells were ab-
lated by the GdCl3 treatment, at the end of
the perfusion experiments the livers were
perfused with China ink (21); histological
examination showed that Kupffer cells from
normal rats but not those from GdCl3-treated
rats were blackish.
To assure that the labeling process did
not impair tPA clearance by the liver, we
perfused the organ with 125I-tPA (2 x 106
cpm) plus unlabeled tPA (500 µg) and veri-
fied that 125I-tPA was cleared (27.4 – 5.2 µg/
min, N = 5) by the isolated, exsanguinated
and perfused rat liver at the same rate (P =
0.422) as unlabeled tPA (27.4 – 5.2 µg/min,
N = 5).
tPA clearance from the circulation
The clearance rates and half-lives of 125I-
tPA were calculated from the plasma elimi-
nation curves for in bolus injection of the
activator in normal or turpentine-treated rats.
The plasma elimination rate of tPA in tur-
pentine-treated rats (2.2 – 0.2 ml/min, N = 7)
decreased significantly (P = 0.016) com-
pared to normal rats (3.2 – 0.3 ml/min, N =
6). The tissue distribution of 125I-tPA is shown
in Figure 1. It can be seen that the AP re-
sponse did not modify the tissue distribution
of the activator and that the liver was the
major site for the efficient removal of 125I-
tPA from the circulation in both normal and
turpentine-treated rats.
Hepatic clearance
Table 1 shows that the inflammatory
stimulus also influenced the clearance of
tPA by the isolated liver. The clearance rate
of tPA by the perfused liver from injured rats
(i.e., treated with turpentine or turpentine-
GdCl3) was slower than observed in normal
animals.
On the other hand, the inflammatory
stimulus had no effect on the clearance rate
of PoPK or TH by the perfused rat liver. The
clearance rate of PoPK (160 µg) (Figure 2A)
by the perfused liver of normal rats (2.4 – 0.1
µg/min, N = 3) was similar (P = 0.830) to that
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Figure 1 - Organ distribution of
125I-tPA 60 min after administra-
tion to normal and turpentine-
treated rats.
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of turpentine-treated rats (2.3 – 0.3 µg/min,
N = 3). Thrombin (50 µg) was efficiently
removed from the circulation by the liver
(Figure 2B) of both normal (34.8 – 2.9 µg/
min) and turpentine-treated rats (39.1 – 2.5
µg/min) (P = 0.321).
Discussion
Receptor-mediated endocytosis is a mech-
anism that transports macromolecules into
the cell following a series of intracellular
transfers through distinct environments. This
process is important for the regulation of the
plasma concentration of many glycoproteins,
and several types of lectins are involved in
the initial step (binding) of the internaliza-
tion process, which can be modified by patho-
logical situations (22).
When complexed with an inhibitor,
thrombin is cleared from the circulation by
hepatocytes via receptor-mediated endocy-
tosis; on the contrary, free TH binds to pa-
renchymal cells but is minimally internal-
ized (15). We now report that the uptake of
free TH by the liver of turpentine-treated rats
is not altered, suggesting that the AP re-
sponse does not modify the binding of TH to
hepatic cells. The hepatic endocytosis of
pancreatic kallikrein is mediated by a specif-
ic mannose receptor (14) found mainly in
liver endothelial and Kupffer cells. In this
study we show that the PoPK clearance by
the liver of turpentine-treated rats is not al-
tered.
It is known that after intravenous infu-
sion of tPA three molecular forms may be
found in plasma: two active forms (free tPA
and the tPA-a2M complex) and an inactive
form (tPA-plasminogen activator inhibitor 1
(PAI-1) complex) (23). Our results showed
that tPA clearance from plasma decreases in
turpentine-treated rats and that the AP re-
sponse does not modify the in vivo tissue
distribution of 125I-tPA, with the liver being
responsible for most of the 125I-tPA cleared
from the circulation even after an inflamma-
Table 1 - Clearance of tPA by the isolated and exsanguinated liver of normal, turpen-
tine- and/or GdCl3-treated rats.
ANOVA, P = 0.003; Bonferroni t-test: a>b; a>d; a = c; b = c; b = d; c = d.
Nonea Turpentineb GdCl3c Turpentine
and GdCl3d
AP response - ++ + ++
(serum a2M)
N 10 4 4 5
Clearance (µg/min) 22.5 ± 0.7 15.5 ± 1.3 17.5 ± 1.4 16.2 ± 2.4
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tory stimulus. We assured that labeling of
tPA with 125I does not impair its clearance by
the liver, a phenomenon described for plasma
kallikrein (18).
In normal rats, human tPA and rat plasma
kallikrein share some characteristics in their
clearance by the liver and a molar excess of
tPA inhibits the hepatic clearance of rat
plasma kallikrein (13), suggesting a com-
mon pathway inside the organ. After an in-
Figure 2 - Clearance of pancreatic
kallikrein (A) and thrombin (B) by
the isolated and exsanguinated
liver of normal or turpentine-
treated rats.
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flammatory stimulus the hepatic clearance
rate of rat plasma kallikrein increased (11),
in contrast to the tPA behavior now de-
scribed. Different behavior during endocy-
tosis of proteins that share a common plasma
membrane receptor has already been de-
scribed: epidermal growth factor and trans-
forming growth factor-a compete for the
same receptor with different affinities, which
could be a consequence of differences in the
mechanisms of intracellular processing (24).
The results reported here suggest that
receptor-mediated endocytosis is not uni-
formly affected by an AP situation. After an
inflammatory stimulus, proteins such as in-
terleukin-6 and transforming growth factor-
ß synthesized by activated Kupffer cells elicit
the AP response in hepatocytes and stellate
cells (25). The clearance rate of tPA by the
liver of turpentine-treated rats was mini-
mally influenced by Kupffer cells since after
their ablation by GdCl3 treatment the clear-
ance rate did not change, in agreement with
the in vivo experiments reported by Narita et
al. (4).
In the present liver perfusion experiments,
we used an amount of tPA comparable to the
dose therapeutically administered to humans
(26). Only when the in vivo administered
tPA overcomes the inhibition by PAI-1 in
plasma will the (free) enzyme be therapeuti-
cally active. It is also known that the throm-
bolytic efficacy of tPA is not correlated with
the dose administered (26). The result re-
ported here showing that free tPA clearance
by the liver is compromised during an AP
situation contributes to the understanding of
this fact.
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